Published in Diabetes Care on January 27, 2011
Cardiovascular biology of the incretin system. Endocr Rev (2012) 2.42
Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans. Diabetes (2015) 1.50
Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc Diabetol (2011) 1.31
Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc (2013) 1.24
Cardiovascular effects of gliptins. Nat Rev Cardiol (2013) 1.23
Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care (2013) 1.03
Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol (2014) 1.00
Vitamin C further improves the protective effect of glucagon-like peptide-1 on acute hypoglycemia-induced oxidative stress, inflammation, and endothelial dysfunction in type 1 diabetes. Diabetes Care (2013) 0.94
Optimising cardioprotection during myocardial ischaemia: targeting potential intracellular pathways with glucagon-like peptide-1. Cardiovasc Diabetol (2014) 0.94
Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS One (2014) 0.92
The vascular endothelium in diabetes--a therapeutic target? Rev Endocr Metab Disord (2013) 0.89
DPP4 in Diabetes. Front Immunol (2015) 0.89
Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc Diabetol (2014) 0.88
Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control. Exp Diabetes Res (2012) 0.86
The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: a preliminary report. Cardiovasc Diabetol (2014) 0.82
Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm. J Am Heart Assoc (2014) 0.82
Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways. Cardiovasc Diabetol (2015) 0.81
Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes. Cardiovasc Diabetol (2013) 0.81
Direct cardiovascular effects of glucagon like peptide-1. Diabetol Metab Syndr (2013) 0.80
Do incretins improve endothelial function? Cardiovasc Diabetol (2014) 0.80
Hyperglycemic endothelial dysfunction: does it happen and does it matter? J Thorac Dis (2015) 0.80
Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis. Sci Rep (2015) 0.79
Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials. J Diabetes Res (2015) 0.79
Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.79
Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals. Exp Ther Med (2014) 0.77
Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension. Diabetol Metab Syndr (2015) 0.76
Postprandial oxidative stress and gastrointestinal hormones: is there a link? PLoS One (2014) 0.76
Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies. Curr Diabetes Rev (2016) 0.75
Protective Role of Glucagon-Like Peptide-1 Against High-Glucose-Induced Endothelial Oxidative Damage. Medicine (Baltimore) (2015) 0.75
Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy. Vasc Med (2017) 0.75
Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol (1979) 27.52
The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 27.07
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol (2002) 16.25
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest (1993) 5.06
Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes (2005) 3.84
Atherogenesis: a postprandial phenomenon. Circulation (1979) 3.74
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab (2004) 3.65
Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol (1999) 2.75
Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes (2007) 2.19
Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia (2001) 2.15
Minireview: the glucagon-like peptides. Endocrinology (2001) 2.15
Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation (2002) 1.97
Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol (2010) 1.68
The effects of plasma insulin and glucose on myocardial blood flow in patients with type 1 diabetes mellitus. J Am Coll Cardiol (2005) 1.66
Incretin-based therapies: review of current clinical trial data. Am J Med (2010) 1.55
Insulin as an anti-inflammatory and antiatherogenic modulator. J Am Coll Cardiol (2009) 1.43
Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes (2010) 1.39
Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care (2007) 1.27
Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med (2010) 1.06
Insulin impairs endothelium-dependent vasodilation independent of insulin sensitivity or lipid profile. Am J Physiol Heart Circ Physiol (2003) 1.01
Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes. Diabet Med (2008) 0.95
Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA (2004) 6.38
Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation (2002) 6.26
Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA (2004) 5.95
Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA (2003) 4.76
Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes (2008) 4.05
Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation (2002) 3.84
Liver enzyme alteration: a guide for clinicians. CMAJ (2005) 3.42
Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int J Cardiol (2012) 3.20
Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann Intern Med (2009) 3.16
Platelet count/spleen diameter ratio for the noninvasive diagnosis of esophageal varices: results of a multicenter, prospective, validation study. Am J Gastroenterol (2006) 2.64
The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol (2011) 2.62
Diet and inflammation: a link to metabolic and cardiovascular diseases. Eur Heart J (2005) 2.46
Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol (2006) 2.26
Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol (2002) 2.23
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation (2004) 2.22
Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care (2012) 2.21
Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr (2011) 2.16
Effects of insulin on left ventricular function during dynamic exercise in overweight and obese subjects. Eur Heart J (2005) 2.12
Striatal volume on magnetic resonance imaging and repetitive behaviors in autism. Biol Psychiatry (2005) 1.94
Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol (2007) 1.86
Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes (2004) 1.84
The effects of diet on inflammation: emphasis on the metabolic syndrome. J Am Coll Cardiol (2006) 1.83
Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med (2003) 1.80
Clinical inertia as a clinical safeguard. JAMA (2011) 1.72
Total thyroidectomy, without prophylactic central lymph node dissection, in the treatment of differentiated thyroid cancer. Clinical retrospective study on 221 cases. Endocrine (2013) 1.72
Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation (2005) 1.71
A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice. J Clin Gastroenterol (2006) 1.69
Role of adipokines in the obesity-inflammation relationship: the effect of fat removal. Plast Reconstr Surg (2006) 1.60
Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab (2003) 1.50
Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab (2008) 1.49
Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes (2002) 1.48
Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. J Clin Gastroenterol (2006) 1.43
Lowering glucose to prevent adverse cardiovascular outcomes in a critical care setting. J Am Coll Cardiol (2009) 1.42
Adherence to Mediterranean diet and erectile dysfunction in men with type 2 diabetes. J Sex Med (2010) 1.42
Effect of rimonabant on weight reduction and cardiovascular risk. Lancet (2005) 1.42
Meal modulation of circulating interleukin 18 and adiponectin concentrations in healthy subjects and in patients with type 2 diabetes mellitus. Am J Clin Nutr (2003) 1.41
Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab (2002) 1.40
Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med (2008) 1.40
Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. Diabetes (2005) 1.37
Mediterranean diet and metabolic diseases. Curr Opin Lipidol (2008) 1.35
Mediterranean diet and weight loss: meta-analysis of randomized controlled trials. Metab Syndr Relat Disord (2010) 1.29
Prevention of type 2 diabetes by dietary patterns: a systematic review of prospective studies and meta-analysis. Metab Syndr Relat Disord (2010) 1.28
Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care (2007) 1.27
Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care (2011) 1.26
Glucose metabolism and hyperglycemia. Am J Clin Nutr (2008) 1.26
Effects of stress hyperglycemia on acute myocardial infarction: role of inflammatory immune process in functional cardiac outcome. Diabetes Care (2003) 1.24
Development and validation of a 6-item version of the female sexual function index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med (2009) 1.22
Antioxidant anti-inflammatory treatment in type 2 diabetes. Diabetes Care (2009) 1.20
Prevention and control of type 2 diabetes by Mediterranean diet: a systematic review. Diabetes Res Clin Pract (2010) 1.18
The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes (2006) 1.16
Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine (2013) 1.15
Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes. Diabetes (2004) 1.15
Semaphorin3A signaling controls Fas (CD95)-mediated apoptosis by promoting Fas translocation into lipid rafts. Blood (2007) 1.14
Mass spectrometry measurement of plasma hepcidin for the prediction of iron overload. Clin Chem Lab Med (2010) 1.11
High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care (2005) 1.10
Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review. Diabetes Res Clin Pract (2010) 1.10
Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol (2002) 1.10
Leukocyte telomere shortening in elderly Type2DM patients with previous myocardial infarction. Atherosclerosis (2009) 1.09
Does personalized diabetology overcome clinical uncertainty and therapeutic inertia in type 2 diabetes? Endocrine (2013) 1.09
Effect of weight loss on cardiac synchronization and proinflammatory cytokines in premenopausal obese women. Diabetes Care (2004) 1.09
Absence of inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in streptozotocin-induced hyperglycemic mice. Diabetes (2004) 1.06
Comment on Khunti et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes care 2013;36:3411-3417. Diabetes Care (2014) 1.06
Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause (2013) 1.06
Telmisartan shows an equivalent effect of vitamin C in further improving endothelial dysfunction after glycemia normalization in type 1 diabetes. Diabetes Care (2007) 1.05
Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. Am J Gastroenterol (2003) 1.05
Cytokine pattern in postmenopause. Maturitas (2002) 1.04
Early changes in bioelectrical estimates of body composition in chronic kidney disease. J Am Soc Nephrol (2006) 1.04
Mitochondrial DNA backgrounds might modulate diabetes complications rather than T2DM as a whole. PLoS One (2011) 1.04
Which diet for prevention of type 2 diabetes? A meta-analysis of prospective studies. Endocrine (2014) 1.04
Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Diabetes Care (2013) 1.03
Endothelial microparticles correlate with endothelial dysfunction in obese women. J Clin Endocrinol Metab (2006) 1.03
Morning blood pressure peak, QT intervals, and sympathetic activity in hypertensive patients. Hypertension (2003) 1.02